NOVAVAX INC
NOVAVAX INC (NVAX): 24 pipeline candidates · 11 upcoming catalysts · ~73 mo cash runway · 11 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
72.5 months
D/E -8.21 · 0% dilution
Lead: Approved
24 candidates
11 upcoming, next in ~541d
N/A
A transparent, data-derived signal for NOVAVAX INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.5B
Cash
$232.9M
Quarterly Burn
$32.4M
Runway
72.5 mo
Revenue
$139.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (24 candidates)
| Drug | Phase |
|---|---|
| cic | Phase 3 |
| cic vaccine co-formulated tniv2 | Phase 3 |
| covid-19 vaccine | Approved |
| covid-19-influenza vaccine candidate | Phase 3 |
| formulation buffer | Phase 3 |
| h5n1 avian pandemic influenza vaccine candidate | Phase 3 |
| icc vaccine | Phase 1/Phase 2 |
| licensed seasonal influenza vaccine | Phase 3 |
| novavax covid-19 vaccine | Phase 3 |
| nuvaxovid | Approved |
Showing 10 of 24 candidates. Sign up for full pipeline.
Upcoming Catalysts (11)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
258
Total value held
$995.3M
| Holder | Shares | Value |
|---|---|---|
| shah capital management | 14,845,097 | $120.8M |
| vanguard capital management llc | 14,260,294 | $116.1M |
| blackrock, inc. | 12,844,319 | $104.6M |
| state street corp | 8,970,518 | $73.0M |
| d. e. shaw & co., inc. | 8,094,658 | $65.9M |
| vanguard portfolio management llc | 7,151,625 | $58.2M |
| bank of america corp /de/ | 6,637,213 | $54.0M |
| geode capital management, llc | 3,898,413 | $31.7M |
| millennium management llc | 3,875,045 | $31.5M |
| coatue management llc | 3,836,986 | $31.2M |
Showing top 10 of 258 institutional holders of NOVAVAX INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in NOVAVAX INC's pipeline?
NOVAVAX INC (NVAX) has 24 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NOVAVAX INC's lead drug candidate?
NOVAVAX INC's most advanced tracked candidate is cic (Phase 3) for COVID-19.
What is NOVAVAX INC's next catalyst?
NOVAVAX INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: VALCYTE" — expected December 11, 2027.
What is NOVAVAX INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NOVAVAX INC has approximately 72.5 months of cash runway.
What is NOVAVAX INC's market capitalization?
NOVAVAX INC's market capitalization is approximately $1.5B.
Get the full picture on NOVAVAX INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.